本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
QINGDAO, China, Jan. 26, 2025 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, has reinforced its dominance in the global TV market achieving an unprecedented three consecutive years of second-highest annual TV shipment volume worldwide. According to the latest report from AVC Revo, Hisense demonstrated exceptional performance in 2024, capturing a significant year-on-year shipment increase of 11.9%, with a shipment share of 14.06%. From 2022 to 2024, Hisense TVs have consistently maintained No. 2 spot in global TV shipments share for three consecutive years. Hisense secures No. 2 spot in global TV shipments for third consecutive year In 2024, Hisense consolidated its position in the worldwide TV market, accounting for 14.06% of global TV shipment share. Benefiting from sponsoring major sporting events and the strong market demand for large screen TV, Hisense achieved a shipment share of 47% in the global 100-inch-and-above TV market in 2024, ranking No.1 worldwide. Driving this success is Hisense's relentless pursuit of technological advancements. At CES 2025, the company unveiled groundbreaking innovations, including the revolutionary 116-inch TriChroma LED TV with RGB Local Dimming Display Technology and the consumer-ready 136-inch MicroLED display, showcasing a bold vision for the future of home entertainment. Hisense is also elevating the TV viewing experience to new heights of personalization and convenience. These innovations will provide fans with immersive experience in the FIFA Club World Cup 2025™. "For me, the three keywords for 2024 were passion, dedication, and innovation." said David Gold, Vice President of Hisense International and President of Hisense Americas. "With these three key words, it's how we were able to really achieve such strong results throughout the year." From driving the innovation of ultra-high definition, intelligent displays to creating seamless AI technology that works behind the scenes; from advancing energy-efficient solutions to driving immersive entertainment experiences, Hisense is committed to technology that is rooted in delivering real value to consumers and improving how people live, connect, and enjoy the moments that matter most. About HisenseHisense is a leading global home appliance and consumer electronics brand. According to Omdia, Hisense ranked No. 2 globally for total TV shipments and No. 1 in 100''+ TVs. The company has rapidly expanded to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.
Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology. Conducted in collaboration with Japan's National Cancer Center Hospital East (NCCHE), the study reveals how Lunit's cutting-edge AI-powered pathology solutions, Lunit SCOPE® HER2 and Lunit SCOPE IO, significantly improve HER2 biomarker evaluation and the prediction of clinical outcomes in metastatic colorectal cancer (mCRC) patients undergoing HER2-targeted therapy. "Lunit SCOPE HER2", Lunit's AI-powered solution designed to detect HER2 expression profile This study presents findings from the TRIUMPH phase II clinical trial, which evaluated 30 patients with HER2-positive metastatic colorectal cancer treated with dual HER2-targeted therapy using Trastuzumab and Pertuzumab. Lunit's AI solutions were applied to assess HER2 status and tumor microenvironment (TME) variables, with significant findings: Enhanced HER2 Assessment Accuracy Lunit SCOPE HER2 demonstrated 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry (IHC), achieving 100% accuracy in identifying HER2 IHC 3+ cases. Improved Prediction of Treatment Response and Outcomes Patients identified by the AI model as having a high proportion of HER2 IHC 3+ staining tumor cells (AI-H3-high, >50%) exhibited better clinical outcomes than those identified through traditional HER2 evaluation methods: Objective Response Rate (ORR): 42.1% (AI-H3-high) vs. 26.7% (overall TRIUMPH trial) Progression-Free Survival (PFS): 4.4 months (AI-H3-high) vs. 1.4 months (AI-H3-low) Overall Survival (OS): 16.5 months (AI-H3-high) vs. 4.1 months (AI-H3-low) Deeper Insights into the Tumor Microenvironment (TME) Using Lunit SCOPE IO, the study performed detailed TME profiling, including lymphocyte, macrophage, and fibroblast densities. Among AI-H3-high patients, those with low stromal TME density (TME-low) achieved the most favorable outcomes: ORR: 57.1% PFS: 5.6 months OS: 26.0 months The findings underscore the transformative potential of AI-powered pathology tools in precision oncology. By providing a more accurate and detailed evaluation of HER2 status and TME characteristics, Lunit's solutions can better stratify patients and predict responses to HER2-targeted therapies currently available or in development. This capability may inform more tailored treatment strategies, ultimately improving patient outcomes in mCRC and potentially other HER2-amplified cancers. "This study underscores the potential of AI technology to redefine how we evaluate biomarkers and predict treatment responses," said Dr. Takayuki Yoshino of the National Cancer Center Hospital East, principal investigator of the research. "The ability to more precisely stratify patients will lead to more personalized treatment options, improving outcomes for patients with HER2-positive metastatic colorectal cancer." "The findings from this study demonstrate how Lunit's AI-powered solutions, Lunit SCOPE HER2 and Lunit SCOPE IO, can provide clinicians with actionable insights to refine treatment strategies," said Brandon Suh, CEO of Lunit. "Our continued collaboration with NCCHE showcases the transformative potential of AI in precision oncology." About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,500 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
STUART, Fla., Jan. 23, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan combines in-person and virtual primary care access with mental health programs, free prescription drugs, lab work, and care navigation for the entire household, all under a low monthly fee and $0 out-of-pocket cost for members. With their cost containment ability proven by numerous third-party actuarial firms and reinsurance carriers, our intention is to utilize Vitable's DPC to provide competitively priced quotes within Health In Tech's proprietary eDIYBS platform for networks and carriers under MARPAI's self-funded health plan offerings. We expect Vitable's high utilization and member satisfaction to contribute to reductions in healthcare costs. "This collaboration exemplifies our commitment to revolutionizing healthcare access and affordability," said Glenn Hillyer, Chief Growth Officer at Health In Tech. "By integrating Vitable's hybrid DPC model - with their successful track record in effectively managing primary care and urgent care claims for self-funded and level-funded plans - with MARPAI's self-funded health plans, and the streamlined process for which Health In Tech is known for, we are working to deliver competitive value and comprehensive care to our clients." Vitable's hybrid DPC model seeks to ensure seamless access to primary care and mental health services, providing members with the flexibility and convenience of both in-home and virtual visits. This approach addresses the critical need for accessible and affordable healthcare, especially for the under- and uninsured workforce. "We are excited to join forces with Health In Tech and MARPAI to bring our high-quality health plans at a significantly lower cost," said Steven Baek, Head of Growth at Vitable. "Our commitment is to enhance member satisfaction and utilization while driving down healthcare costs." "We are excited to announce our collaboration with both Health In Tech and Vitable, two leaders in the employee benefits space," said Ben Utz, Vice President of Strategic Accounts at Marpai. "Together, we hope to deliver smarter, seamless healthcare experiences that prioritize employee well-being, improve access to personalized care, and drive meaningful results for organizations." This competitive quote opportunity will be available through Health In Tech's eDIYBS platform starting today. About Health In Tech Health In Tech (Nasdaq: "HIT") is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com. About Vitable Vitable offers a hybrid Direct Primary Care health plan for self-funded and level-funded groups, delivering easy access to high-quality primary care and mental health coverage to the under- and uninsured American workforce. Vitable membership includes in-home and virtual primary care visits, free prescriptions, labs, and mental health programs with no out-of-pocket cost for the members. About Marpai, Inc. Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna, industry leading Reference Based Pricing (RBP) solutions and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://www.ir.marpaihealth.com. Forward-Looking Statements Regarding Health In Tech Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech's operations, results of operations, growth strategy and liquidity. Investor Contact Investor Relations:ir@healthintech.com
First shared at a recent Japanese Society of Digital Pathology meeting, the company is forging a global alliance with a leading US medical institution and other organizations to harness technology for better patient care and outcomes in oncology. TAIPEI, Jan. 22, 2025 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, is unveiling its vision for AI and 3D digital pathology to advance patient-centered care. The vision was first detailed publicly by Dr. Yen-Yin Lin, CEO of JelloX, during the August 2024 Annual Meeting of the Japanese Society of Digital Pathology. JelloX continues to distinguish itself as an early adopter of AI and 3D imaging applied to cancer pathology. "Technological advancements and the recent surge in AI have reshaped the future of healthcare, enabling the extraction of valuable insights that will have real benefits for patients," shared Dr. Lin. "3D pathology can offer at least 50 times more information than conventional 2D methods, providing pathologists with a more comprehensive understanding of a tumor's biology. The power of such a diagnostic tool lies in its ability to help pathologists stratify and personalize, matching the right patients with the right treatment at the right time. This ultimately leads to better prognosis, quality of life, and more patient-centered care." Improving patient-centered care with technology JelloX has previously estimated that 40% of cancer patients can benefit from AI-analyzed 3D imaging for pathology by expanding feasibility of treatment options like immunotherapy. Due to the complexity of cancer and variability between cases, these technologies hold significant promise for oncology, particularly in addressing the challenge of limited information from conventional methods. With the increased sampling rate via 3D imaging analyzed by AI, pathologists have more actionable insights regarding the tumor, assisting them in making a wholistic diagnosis. Patients who were previously excluded from immunotherapy due to undetected biomarker expressions, resulting from the limitations of current techniques, may now have a renewed opportunity. With its improved sensitivity, 3D pathology can not only identify cases previously classified as "false negatives" but also enable early cancer detection. This allows for earlier treatment initiation, leading to an improved quality of life for patients. For healthcare providers, this means matching the right patients to the right drugs at the right time. For patients, more precision for diagnosis, treatment, and timing means lowered risk of misdiagnosis, minimized patient costs, and better prognosis—ultimately to more patient-centered care and better quality of life. A visionary new platform Dr. Lin continued: "The fight against cancer is not a one-on-one battle, so partnerships are crucial to accomplish this. JelloX has embraced collaboration across countries and industries to build an AI-powered 3D pathology platform together." In collaboration with a leading US medical center and other partners, JelloX is developing a platform that can address multiple pain points for patients and the healthcare industry. The platform will leverage JelloX's software, MetaLite®, which recently received 510(k) clearance from the US Food and Drug Administration. In addition to the benefits for patients, an AI-powered 3D pathology platform that continuously grows could greatly accelerate biomarker research and benefit the healthcare industry. Over time, the platform could continue to grow more precise at cancer diagnosis as it learns from sample biomarkers paired with anonymized patient outcome data. Also, as the platform finds novel biomarkers, it could facilitate development of new technologies and their commercialization. About JelloX Biotech Inc. Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a startup which focus on advancing cancer pathology through 3D digital imaging and AI technology. For more information, please visit: https://jellox.com/en/home/
Elite, Regular, and Foundation Programs Available - Top Tutors Help Students Reach Their Full PotentialHONG KONG SAR - Media OutReach Newswire - 22 January 2025 - The Learn Smart Education (LSE) team, which came together during the pandemic in 2021, started with only a handful of teachers but has persevered through challenges to achieve remarkable success. By 2024, the team has nurtured numerous students who have excelled in the HKDSE, with some achieving top-tier results as second and third place scorers. Recently, LSE announced the launch of its self-developed AI learning system, which adheres to the philosophy of "designing the most effective learning solutions for students." This innovative system enhances teaching efficiency and accelerates students' learning progress by leveraging advanced AI technology. It analyzes students’ strengths and weaknesses, providing targeted support for weaker areas, and offers personalized learning plans tailored to each student’s needs. Elite, Regular, and Foundation Programs Available - Top Tutors Help Students Reach Their Full Potential LSE is renowned for its highly efficient learning environment, where students can seamlessly engage with teachers in an interactive and enjoyable setting that further inspires their motivation to learn. The team members are all highly experienced educators, and its star tutors in various disciplines are graduates of the world’s top universities. Each tutor specializes in their respective subject and brings over five years of tutoring experience, ensuring a high level of teaching quality. Students at Learn Smart Education consistently achieve outstanding results in the Hong Kong Diploma of Secondary Education (HKDSE) each year. Over the years, LSE has cultivated multiple second and third place scorers in the HKDSE, solidifying its reputation for excellence. 1 to 1 Personalized Learning with AI-Powered Analysis Unlike traditional teaching methods, LSE prioritizes individual students’ needs. Its in-house curriculum development team crafts intensive courses, and the advanced AI system analyzes students' strengths and weaknesses, providing personalized learning plans with targeted support for areas needing improvement. This approach empowers students to identify their strengths while addressing weaknesses effectively, maximizing learning outcomes. The LSE student app features an enrollment system and practice exercises in both Chinese and English. For example, in Classical Chinese literature practice, teachers input passages and translations, selecting difficulty levels. The AI then generates practice questions and suggested answers. After completion, the system uses big data to analyze student performance, comparing it to peers and providing accurate predictive assessments. LSE offers a diverse range of secondary school courses, covering Chinese, English, Mathematics, and other subjects for students from Forms 1 to 6. Three learning pathways – advanced, regular, and remedial – ensure students start at an appropriate level, gradually building their foundation and improving their learning effectiveness. All teachers are graduates of top universities with extensive teaching experience, providing high-quality instruction. Unlimited Chinese and English essay feedback and unlimited mathematics practice opportunities are included, promoting holistic development and improved learning outcomes. Free DSE Strategy Workshops and Mock Exams LSE regularly hosts free one-day DSE strategy workshops and a pre-exam "Register for One Subject, Practice All Subjects Free" campaign, providing additional practice opportunities for students with limited time or resources. Large-scale mock exams help students identify and address weaknesses, preparing them for the DSE examinations and fostering continuous improvement. Industry Recognition and Future Plans LSE has received numerous accolades, including the Most Outstanding Classroom Awards and recognition in the Second Mega Rich Family Good Employer Award Program. LSE continuously refines its teaching system, offering increasingly personalized learning solutions tailored to individual student needs. The institution is dedicated to developing strategies to enhance student motivation, encouraging practical application of classroom learning and continuous self-improvement. With the introduction of AI Systems and a series of effective initiatives, LSE aims to provide a superior learning experience, empowering students to overcome academic challenges and build a brighter future. Hashtag: #LearnSmartEducation #AILearningSystem #AISystem #SecondaryCareer #EnhancementCourses #DSEexam #examtips #DSEprepare #HKTUTOR #Tuitionteacher #parentrelationship #Concentration #TutorThe issuer is solely responsible for the content of this announcement.Learn Smart EducationCurrently operating four campuses in North Point, Prince Edward, and Mong Kok, Learn Smart Education boasts top-tier tutors in each subject. These tutors are graduates of prestigious universities, specializing in their respective fields with over five years of tutoring experience, guaranteeing expertise. Address︰ North Point Java Road：7/F, 108 Java Road, North Point North Point King’s Road：2/F, 383 King’s Road, North Point Prince Edward Building：5/F, Central Commercial Tower, 736 Nathan Road, Mong Kok Mong Kok Building：6/F, Hua Chiao Commercial Centre, 678 Nathan Road, Mong Kok WhatsApp：852 5950 5987 Tel︰852 3580 8982 Website: https://learnsmart.edu.hk/ Facebook: https://www.facebook.com/LearnSmartEducation Instagram: https://www.instagram.com/learnsmarteduhk/
Yanolja Platform and Interpark Triple unite to create a B2C mega-platform Maximizing platform synergy to pioneer a new path in the leisure and travel industries SEOUL, South Korea, Jan. 21, 2025 /PRNewswire/ -- Beyond Leisure, Transforming Everyday Life. Two of South Korea's leading online travel and leisure platforms, Yanolja Platform and Interpark Triple, have merged to form a new integrated corporation, Nol Universe (Co-CEOs: Bae Bo-chan and Choi Hwi-young). Nol Universe aims to be a comprehensive platform that transcends the traditional leisure industry—encompassing flights, accommodations, package tours, tickets, entertainment, culture, and the arts—while also innovating across everyday experiences such as dining, shopping, and community engagement. The name Nol Universe blends the Korean word "Nol" (meaning "play") with the limitless possibilities of a "universe," reflecting the company's mission to provide boundless, extraordinary experiences. By combining the expertise of two industry leaders—companies that have operated at the largest scale and for the longest time in South Korea's travel, leisure, and cultural industries—Nol Universe symbolizes a bold new chapter, building a broader and more dynamic platform to reshape the future of leisure and travel. Leveraging its extensive, long-accumulated database and cutting-edge ontology-based AI technology, Nol Universe delivers hyper-personalized user experiences. Beyond being a service provider, it will also act as a dynamic communication hub, constantly engaging with customers and delivering timely, relevant information. As one of the largest travel and leisure platforms in Asia, Nol Universe aspires to become a global powerhouse in the industry through collaboration and competition with leading online travel agencies (OTAs) worldwide. The company will operate under the dual leadership of Bae Bo-han, CEO of Yanolja Platform, and Choi Hwi-young, CEO of Interpark Triple. Its headquarters are located in Pangyo 2nd Techno Valley, Gyeonggi Province, South Korea. Lee Su-jin, CEO of Yanolja Group, stated, "We are dedicated to expanding happiness in both the everyday and extraordinary moments of our customers' lives. Nol Universe will pave a new path in the domestic and global travel and leisure markets by maximizing platform synergy, offering differentiated services, and leveraging exceptional technology." [About Nol Universe] Nol Universe is a comprehensive platform company that reimagines experiences across both travel—such as flights, accommodations, and package tours—and daily life, including entertainment, culture, and the arts. By integrating platforms such as Yanolja, a global leisure platform; Interpark, South Korea's leading travel and entertainment service; Triple, an ultra-personalized travel platform; and Triple Korea, catering specifically to international tourists visiting South Korea, Nol Universe is dedicated to bringing happiness into everyday life, going beyond leisure, and making it easy for everyone to relax and enjoy. By utilizing its vast data resources and AI-driven personalization, Nol Universe delivers innovative, tailored experiences to its users. Through seamless interconnection and synergy across its platforms, Nol Universe connects diverse customer touchpoints, creating moments of delight and amazement that go far beyond expectations.
A12 藝術空間
AI technology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
